EntryPoint Capital’s Taysha Gene Therapies TSHA Stock Holding History

EntryPoint Capital’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-69,109	Closed	-$160K	–	875
2025 Q2	$160K	Sell	69,109 -66,788	-49%	-$145K	0.08%	527
2025 Q1	$189K	Buy	135,897 +74,402	+121%	+$124K	0.09%	550
2024 Q4	$106K	Buy	61,495 +34,468	+128%	+$71.5K	0.04%	664
2024 Q3	$54.3K	Buy	+27,027	New	+$59.3K	0.03%	586
2024 Q2	–	Sell	-122,905	Closed	-$353K	–	1621
2024 Q1	$353K	Sell	122,905 -168,711	-58%	-$352K	0.32%	9
2023 Q4	$516K	Buy	+291,616	New	+$581K	0.49%	5

Other funds holding TSHA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

EntryPoint Capital's TSHA Position: Q3 2025 in Review

EntryPoint Capital sold out of Taysha Gene Therapies (TSHA) in Q3 2025, closing a stake of 69,109 shares — an estimated $160K sold.

EntryPoint Capital first reported a position in TSHA in Q4 2023 and held it in 6 quarters. The position peaked at $516K in Q4 2023. 155 funds tracked by Wall St. Rank hold TSHA as of Q3 2025.

EntryPoint Capital reported no remaining Taysha Gene Therapies position as of Q3 2025 after selling out during the quarter.
EntryPoint Capital sold 69,109 Taysha Gene Therapies shares in Q3 2025, an estimated $160K.
EntryPoint Capital first reported a position in Taysha Gene Therapies in Q4 2023 and held it in 6 quarters.
EntryPoint Capital's Taysha Gene Therapies position peaked at $516K in Q4 2023.
155 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2025.

Based on EntryPoint Capital's 13F filing for Q3 2025, filed 13 Nov 2025.